Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IP6K1 | Q92551 | 4/20 | 0.80 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.54 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.53 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.53 |
| ▸ | PARP1 | P09874 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | NSD2 | O96028 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.51 |
| ▸ | CTSV | O60911 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7450965 | 0.88 | IP6K1 (0.62) | IP6K1ROCK2PARP1SMN1; SMN2TNKS2 | |
| SCHEMBL5875318 | 0.86 | IP6K1 (0.61) | IP6K1IP6K3PARP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL5875474 | 0.86 | IP6K1 (0.60) | IP6K1PARP1MAOBMAOAACHE | |
| SCHEMBL3527436 | 0.83 | IP6K1 (0.60) | IP6K1SMN1; SMN2NSD2ABL1PPARG | |
| SCHEMBL20897397 | 0.82 | IP6K1 (0.69) | IP6K1ROCK2IP6K3IP6K2PARP1 | |
| SCHEMBL4116942 | 0.80 | IP6K1 (0.62) | IP6K1NSD2ABL1PPARGRIN1 | |
| SCHEMBL3275718 | 0.78 | IP6K1 (0.61) | IP6K1IP6K3IP6K2NSD2ABL1 | |
| SCHEMBL3275884 | 0.78 | IP6K1 (0.61) | IP6K1ROCK2IP6K3IP6K2PARP1 | |
| SCHEMBL29717506 | 0.78 | IP6K1 (0.61) | IP6K1ROCK2IP6K3IP6K2PARP1 | |
| SCHEMBL29717416 | 0.78 | IP6K1 (0.61) | IP6K1IP6K3IP6K2NSD2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025235874-A1 | HETEROCYCLICS AS EGFR INHIBITORS | SCHRÖDINGER, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| US-10053430-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORP. (US) | 2018-08-21 | — | — | US | disclosed |
| EP-2268623-B9 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20170298029-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2017-10-19 | — | — | US | disclosed |
| US-9730937-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| EP-3147281-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2017-03-29 | — | — | EP | disclosed |
| US-9567358-B2 | Methods of treatment using N-(3-fluorophenyl)-2-{3-[(7-{3-[ethyl(2-hydroxyethyl)amino]propoxy}-quinazolin-4-yl)amino]-1H-pyrazol-5-yl}acetamide | ASTRAZENECA AB (SE) | 2017-02-14 | — | — | US | disclosed |
| CN-106146484-A | Quinazoline derivant is as RAF kinase modulator and their method and purposes | 埃姆比特生物科学公司 | 2016-11-23 | — | — | CN | disclosed |
| US-20160199375-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. | 2016-07-14 | — | — | US | disclosed |
| CN-102026985-B | Quinazoline derivatives as RAF kinase modulators and methods and uses thereof | 埃姆比特生物科学公司 | 2016-07-06 | — | — | CN | disclosed |
| US-5962458-A | ANGIOGENESIS INHIBITORS, ANTICANCER AGENTS, ANTIDIABETIC AGENTS, SKIN DISORDERS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS, VISION DEFECTS | ZENECA LIMITED (GB) | 1999-10-05 | — | — | US | disclosed |
| EP-0912557-A1 | OXINDOLE DERIVATIVES | ZENECA LIMITED (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1999010349-A1 | OXINDOLYLQUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ZENECA LIMITED (GB) | 1999-03-04 | — | — | WO | disclosed |
| EP-0885198-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-12-23 | — | — | EP | disclosed |
| EP-0880508-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ZENECA LIMITED (GB) | 1998-12-02 | — | — | EP | disclosed |
| EP-0873319-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-10-28 | — | — | EP | disclosed |
| WO-1997042187-A1 | OXINDOLE DERIVATIVES | ZENECA LIMITED (GB) | 1997-11-13 | — | — | WO | disclosed |
| WO-1997032856-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-09-12 | — | — | WO | disclosed |
| WO-1997030035-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ZENECA LIMITED (GB) | 1997-08-21 | — | — | WO | disclosed |
| WO-1997022596-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053430-B2 | RAF kinase modulator compounds and methods of use thereof | BRAF, RAF1, ARAF | IP6K1 267/4885ROCK2 401/4885IP6K3 324/4885 |
| US-20160199375-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | IP6K1 267/4885ROCK2 401/4885IP6K3 324/4885 |
| US-20170298029-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | IP6K1 267/4885ROCK2 401/4885IP6K3 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.